NCT00080288View on ClinicalTrials.gov

Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD

PHASE3CompletedINTERVENTIONAL

Enrollment

254

Participants

Timeline

Start Date

March 31, 2004

Study Completion Date

December 31, 2004

Conditions

Excessive SleepinessShift Work Sleep Disorder

Interventions

DRUG

Armodafinil 150 mg/day

Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.

DRUG

Placebo

Matching placebo tablets once daily

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Cephalon

INDUSTRY